



## Hereditary Syndromes and Radiation

Guest Editors:

### **Dr. Ana Margarida Abrantes**

1. Biophysics Institute of Faculty of Medicine, Coimbra Institute for Clinical and Biomedical Research (iCBER) Area of Environment Genetics and Oncobiology (CIMAGO), University of Coimbra, 3000-354 Coimbra, Portugal  
2. Center for Innovative Biomedicine and Biotechnology (CIBB), 3000-354 Coimbra, Portugal

### **Prof. Dr. Guillaume Vogin**

1. Centre François Baclesse, 4240 Ezch-sur-Alzette, Luxembourg  
2. UMR 7365 CNRS-UL IMOPA, Équipe 1, Faculté de Médecine, 54505 Vandœuvre-lès-Nancy, France

### **Message from the Guest Editors**

About 5% of all cancers are part of a hereditary cancer syndrome. Concerning the use of radiation for cancer treatment, recommendations are established under the assumption that the general population has relatively uniform radiation sensitivity, excluding a few known rare radiation sensitivity-related clinical syndromes. As the availability of genetic tests increases, questions arise in clinical practice as to whether DNA mutations are related to repair pathways that have not been well studied with regard to radiation effects. Potential topics for this Special Issue include, but are not limited to, genetic cancer syndromes, ionizing radiation effects, cell repair mechanisms in genetic cancer syndromes, radiation therapy, ionizing radiation effect diagnostic methods, and new insights into hereditary cancer syndromes.

Deadline for manuscript submissions:

**closed (30 September 2023)**





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)